ESTRO 2022 - Abstract Book

S1025

Abstract book

ESTRO 2022

Partial breast irradiation (PBI) with intraoperative radiotherapy (IORT) has been implemented as a safe alternative to classic external beam whole breast irradiation (WBI) for low-risk early-stage breast cancer patients after breast conserving surgery. We present the experience at our center treating patients with PBI using an IORT technic with Xoft® Axxent® Electronic Brachytherapy (eBx®) System®. Materials and Methods Between April 2019 and August 2021, 44 patients diagnosed with low-risk early-stage breast cancer who met international criteria for PBI, received IORT in a single fraction of 20 Gy to the tumor bed after lumpectomy. Toxicities and follow up were prospectively registered. Results 3 of the 44 initial patients were discarded for IORT due to non-compliance with the minimum safety distance (<1 cm) between the applicator and the skin. Of the remaining patients, 32/41 patients (78%) received a PBI, while 9/41 (22%) required adjuvant WBI due to adverse prognostic factors identified on the definitive biopsy. The most frequent risk factor was close resection margins (<2mm), present in 8/9 patients (88,8%). Two patients additionally presented sentinel node involvement and in 1 case no axillary sample was obtained. The most used IORT applicator was the 3-4 cm balloon, with most likely filling volumes between 30cc and 40 cc. For all treatments, the mean filling volume of the applicator was 45 cc and there were no complications during the irradiation procedure. Surgical bed seroma was the most common acute effect, observed in 29/41 patients (70,7%), although only 8/29 (27,5%) required drainage. We observed wound dehiscence in 7/41 cases (17%), inflammatory complications requiring antibiotics in 9/41 cases (19,5%), and 4/41 cases of hematoma (9,7%). Regarding late toxicity, at the time of the analysis it was only assessable for 37 patients. We observed low rates of local grade I fibrosis (21,6%) and only 1 case of tumor bed G2 fibrosis. Hyperpigmentation G1 was observed in 8,1% of patients and 10,8% presented occasional mild local discomfort. With median follow-up of 17.14 months (range 4-29 months), no relapses were observed, but 1 patient died from covid-19 pneumonia. Conclusion Intra operative PBI with Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a feasible approach to treat low-risk early-stage breast cancer patients. Our preliminary results show that it presents advantages over conventional WBI allowing for less toxic and shortened treatment courses while maintaining good local tumor control. Purpose or Objective This study aimed to assess prevalence and types of sexual dysfunction in young breast cancer (BC) survivors and to analyse the impact of cancer diagnosis and treatment’s related factors on sexual functioning. Materials and Methods We performed a cross-sectional study including all young BC patients ( ≤ 40 year-old) who have been irradiated in the Ariana's Radiation Oncology Department since at least 6 months. Patients were recruited to fill in the Female Sexual Function Index (FSFI) in its validated Arabic translated version. Demographic and clinical data were collected. Statistical association between these variables and sexual dysfunction was analysed. Results One hundred and two medical records of eligible breast cancer patients were reviewed. Only 40 (39.2%) patients accepted to answer the questionnaire. Mean age was 36 years. Eighty-two percent of patients had stage T1-T2 BC and 56% had positive regional lymph nodes. Radical mastectomy was performed in 73% of cases. Thirty-nine (97%) patients underwent chemotherapy which was poorly to moderately tolerated in 55% of cases. Endocrine therapy was prescribed for 31 (77%) women with ovarian function suppression in 96,77% of the cases. All women underwent adjuvant hypofractionated RT. Twenty-eight (70%) patients experienced skin toxicity: 14 patients had skin colour changes, 8 reported breast asymmetry and 7 patients had skin dryness. Only 2 patients underwent breast reconstruction. Sexual dysfunction before BC diagnosis was reported in 2 patients. The mean FSFI full score was 24.01 (2-33). Fifty-five percent of participants had female sexual dysfunction with FSFI full score <26.55. Hypoactive sexual desire disorder was reported in 92% of cases with mean desire score of 3,5 (1.2-5.4), whereas 60% had arousal disorder. Ten patients (40%) reported lubrication difficulties. The mean orgasm and satisfaction scores were 4.23 and 4.44 respectively, with 44% of women reporting a subjective deterioration of sexual well-being. Although not statistically significant, women who underwent radical surgery and ovarian suppression function tended to have poorer sexual function. Neither chemotherapy, radiotherapy nor treatment’s related toxicities were associated to sexual dysfunction. Conclusion This study showed high prevalence of female sexual disorders in young BC survivors. BC diagnosis and treatment may significantly impair patient’s sexual function. Assessment and management of sexual dysfunction should be part of our standard care. Larger studies with further analysis of sexual dysfunction predictors are required to improve BC survivor’s sexual outcomes and quality of life. PO-1208 Sexual health in young breast cancer survivors: What is hidden behind taboo and health priorities? Z. Naimi 1 , M. El Bessi 1 , M. Bohli 1 , B.A. Raouia 1 , A. Hamdoun 1 , J. Yahyaoui 1 , L. Kochbati 1 1 Abderrahmen Mami Hospital Ariana, Radiation Oncology Department, Ariana, Tunisia

PO-1209 SBRT IN WOMEN OVER 70 YEARS OLD WITH EARLY BREAST CANCER